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Abstract
Pakistan is among four countries in Asia where the estimated number of new HIV infections has been increasing year by
year ever since 1990. The Asian Epidemic Modelling (AEM), conducted in 2015, reconfirmed that the use of contaminated
injection equipment among people who inject drugs (PWID) remains the main mode of HIV transmission in the country.
The estimated number of PWID ranges from 104,804 to 420,000 PWID. HIV prevalence in this population is above 40 % in
several cities, including Faisalabad (52.5 %), D.G. Khan (49.6 %), Gujrat (46.2 %), Karachi (42.2 %) and Sargodha (40.6 %),
respectively. Harm reduction service delivery is being implemented through a public-private partnership led by the
National and Provincial AIDS Control Programmes and Nai Zindagi with funding support from the Global Fund. Current
programmatic coverage of the needle and syringe programme, HIV testing and counselling and antiretroviral treatment
among PWID remain insufficient to control ongoing transmission of HIV in the country. While opioid substitution therapy
(OST) is yet to be introduced, significant progress and coordination among various ministries have taken place recently to
register buprenorphine in the dosage required for treatment of opioid dependence, and possible introduction of OST will
greatly facilitate adherence to antiretroviral treatment among PWID living with HIV.
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Introduction
It has been nearly 30 years since the first AIDS case was
diagnosed in Pakistan in 1986 [1]. Since then, transmission
of HIV has continued in a slow but steady manner.
Pakistan is among four countries in Asia, along with
Indonesia, Malaysia and the Philippines, where the HIV
epidemic is expanding with a number of new HIV infec-
tions higher each year than the previous year with an esti-
mated 15,606 new infections in 2014 alone. Injection drug
use remains a major mode of ongoing transmission of
HIV in the country. According to the 2014 World Drug
Report by United Nations Office of Drugs and Crime
(UNODC), while it has been estimated that an average of
13.1 % of people who inject drugs (PWID) worldwide are
living with HIV, HIV prevalence in this population is high-
est in South-West Asia (28.8 %), followed by Eastern and
South-Eastern Europe (23.0 %), respectively, and the high
prevalence of HIV among PWID in the South-West Asia
region is predominantly accounted for by high prevalence
of HIV among PWID in Pakistan. This paper reviews the
epidemiology of and response to addressing drug-related
HIV epidemics in Pakistan, drawing from published and
unpublished literature.
Review
Epidemiology of injection drug use and HIV/AIDS among
people who inject drugs and their intimate partners
An estimated 91,340 people (range 61,000–128,000) were
living with HIV as of December 2014 and another 15,606
people (range 7000–33,000) became newly infected with
HIV in that year [2]. While the overall prevalence of HIV
among 15–49-year olds in the country has remained below
1 % (0.8 % in 2014), HIV prevalence among street-based
PWID is among the highest reported in Asia and recent
modes of transmission studies project an increase of trans-
mission among men who have sex with men. A cohort
study of 636 HIV seronegative PWID who were registered
with three drop-in centres in Karachi found incidence of
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HIV to be 12.4 per 100 person-years (95 % exact Poisson
confidence interval 10.3–14.9) which is high considering
that the PWID were attending harm reduction services.
Daily injection of drugs, sharing of syringes, being homeless
and non-Muslim religion were found to be predictors of
HIV seroconversion in the multivariable Cox Regression
analyses [3].
While concerned stakeholders await for the findings
of the fifth round of Integrated Biologic and Behavioral
Surveillance Survey (IBBS) which is in the process of
being implemented during 2015, the main source of
information on behaviours that place PWID and their
intimate partners at risk of HIV and other blood-borne
viruses used to inform the national strategic planning
and monitoring of the HIV response at the moment
remains the IBBS which was conducted in 2011 [4].
In the 2011 round of IBBS, 4956 PWID were recruited
and interviewed. Their average age was 30.4 years and
33.8 % were married while 57.1 % had no education. Ma-
jority (71.5 %) injected two to three times a day and most
(90.5 %) had their last injection on streets or open spaces,
whereas 80.9 % injected with friends and acquaintances.
Only 38.6 % reported “always using a new syringe” for
drug injection. Sharing of injection equipment for the last
injection was reported by 39.2 % of the PWID. Sex with a
regular female partner in the past 6 months was reported
by 26.4 % of the PWID, and condom use at the last sexual
act was reported by 25.8 %. Seven per cent PWID reported
having had sex with a male sex worker or hijra sex workers
in the past 6 months. Up-to-date information on HIV
prevalence in this population is not available since the
most recent sentinel survey was conducted in 2011 with
the exception of programme data derived from HIV testing
and counselling sites based on which the overall HIV
prevalence among PWID was 33 % [5].
The 2011 IBBS also provides a glimpse of intermixing of
key populations. Altogether, 10.1 % male and hijra sex
workers had sex with PWID while 7.1 % PWID had paid a
male or hijra sex worker for sex in the past 6 months. A
sizeable proportion of FSWs (10.8 %) had sex with PWID
in the previous 6 months. A total of 76 HIV samples were
analysed from men who have sex with men (MSM), their
female spouses and children, along with 26 samples from a
previously studied cohort of PWID. Phylogenetic analysis
of HIV gag gene sequences obtained from these samples
indicated a substantial degree of intermixing between the
PWID and MSM populations, suggesting a bridging of
HIV infection from PWID, via MSM, to the spouses and
children of MSM.
According to data from the 2011 IBBS, HIV prevalence
among PWID has steadily increased from 10.8 % in 2005
to 27.2 % in 2011. HIV prevalence in this population is
above 40 % in several cities, including Faisalabad (52.5 %),
D.G. Khan (49.6 %), Gujrat (46.2 %), Karachi (42.2 %) and
Sargodha (40.6 %), respectively. The latest round of IBBS
in the province of Punjab, conducted in 2014, indicated a
weighted prevalence of 36.8 % among ten cities of Punjab.
Based on a model by Reza et al. [6], HIV prevalence may
increase to 65–75 % among PWID in Faisalabad, 46–66 %
among PWID in Karachi, 44–49 % among PWID in
Lahore by 2015 and the total number of people who inject
drugs infected with HIV may reach 68,000 by 2020.
Intimate partners of men who inject drugs are especially
vulnerable to acquiring HIV infection. For example, within
a short space of time after the initial HIV epidemic
outbreak among men who injected drugs in Manipur,
Northeast India, in 1989, HIV prevalence among wives
of the men had reached 45 % [7]. In Pakistan, information
about HIV risk and vulnerability of female spouses of
PWID is available from a cross-sectional survey of men,
and their spouses, who were accessing street-based harm
reduction services provided by Nai Zindagi in three cities
of the country. The survey of 459 husband and wife couples
revealed 28 % HIV prevalence among the male PWID and
15 % HIV prevalence among their wives in Faisalabad, 10 %
in Lahore and 5 % in Sargodha, respectively. Since none of
the women interviewed reported having injected drugs, the
main mode of HIV transmission among the women was
assumed to be sexual transmission from their husbands.
On average, couples that were surveyed had four children,
20 % were breastfeeding and 8 % were pregnant at the time
of the survey illustrating the high risk of non-injecting
spouses and their babies in acquiring HIV [8]. The most
recent data on HIV prevalence among wives of PWID is
available from programme data collected from the 28 sites
which deliver harm reduction services with funding support
from the Global Fund to Fight AIDS, Tuberculosis and
Malaria (GFATM). Among female spouses of PWID, 7 % of
the spouses were found to be infected with HIV with the
highest prevalence in Balochistan (29 %) [9].
Prevalence of HBV and HCV among PWID
Data on prevalence of hepatitis B and hepatitis C among
PWID in Pakistan is scarce. The latest available data is
from 2003 to 2004 at which time 6.8 % (range 6.0–7.5 %)
of PWID were found HBsAg positive and 84.0 % (range
75.0–92.9 %) HCV positive, respectively [10]. A cross-
sectional study of 161 PWID conducted in 2003 in
Karachi found 94.3 % hepatitis C positive while prevalence
of hepatitis B was 7.5 % [11].
Discussions are underway regarding the need to assess
current prevalence of HCV among PWID. In a descriptive
observational study of 162 HIV-positive men, including 81
PWID and 81 men who did not inject drugs, conducted at
an HIV treatment and care centre at the Pakistan Institute
of Medical Sciences (PIMS) hospital, Islamabad, 66 (77.8 %)
of PWID tested positive for HBsAg, while only five (6.2 %)
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of the patients who did not inject drugs were found to have
hepatitis C [12].
HIV among prisoners
As of December 2013, there were 104 prisons in Pakistan
with a total capacity for 45,587 prisoners. The actual
number of prisoners as of 31 December 2013 was 77,504
(170 % of the authorised accommodation) among whom
2408 (3.1 %) were “drug addicts/users” [13]. Drug use,
including injection drug use, and unprotected sexual behav-
iour resulting in transmission of HIV and other blood-
borne infections in prisons cannot be ruled out presenting
significant challenges for prison management and public
health authorities.
For example, following screening of 43,000 prison
inmates in Punjab province in 2009, 231 (0.54 %) were
found infected with HIV [14]. In another study in one
prison in Punjab, 4.4 % of 1000 prisoners tested HIV
positive while prevalence of HCV was 19.7 %, with
3.7 % co-infected with HIV and HCV [14].
In 2012, UNODC Pakistan Country Office commissioned
a bio-behavioural study in five prisons in Sindh province
with the objectives to explore HIV risk and vulnerability
among prisoners as well as to assess HIV prevalence among
the prison inmates [15]. A total of 1198 interviews were
conducted with inmates all of whom were tested for HIV.
Opium and heroin use “ever” was reported by 15 and 16 %
of the inmates, respectively, while of those reporting drug
use, 32.9 and 50.9 % reported having used drugs in prison.
“Ever use” of injection drugs was reported by 9.8 % of the
inmates. Injection drug use within prisons was reported by
12.3 % among those who reported having ever injected
drugs. The overall HIV prevalence across the five prisons
was 2.3 %, considerably higher than the overall national
prevalence of HIV among adults (15–29) which is <0.1 %.
Central Jail Hyderabad reported the highest HIV prevalence
among the prisoners at 3.7 %, followed by 2.9 % in Central
Jail Sukkur.
Extent and nature of drug use
In 2013, a national survey on drug use was conducted by
the Pakistan Bureau of Statistics, in coordination with the
Narcotics Control Division and with support from
UNODC and the United Nations Country Team [16]. The
national survey consisted of five components: a household
survey of 51,000 respondents randomly selected in house-
holds across the country; a problem drug use survey, con-
sisting of interviews with 4500 individuals who had used
illicit substances on a regular basis (in the past 12 months
and 30 days) for non-therapeutic purposes in 23 districts;
interviews with 1200 key informants (23 districts); an
audit of drug treatment services (across the country); and
an audit of drug-related arrest data. The interviews with
the “problem drug users” were conducted in community
settings using snowball sampling strategy.
The findings from the household survey indicated that an
estimated 860,000 people, or 0.8 % of the population aged
15–64, used heroin regularly. Based on the findings from
the problem drug use survey, an estimated 430,000 (range
190,000 to 657,000), or 0.4 % (range 0.3 to 0.5 %) people
aged 15–64, inject drugs. Among these, 78 % injected her-
oin and the remaining injected pharmaceutical opioids,
including morphine, pentazocine or pethidine, and tran-
quilisers for non-therapeutic purposes. Poly drug use was
a common phenomenon with over 75 % of opioid users
injecting a combination of substances. In this survey,
the majority reported injecting two to four times a day.
According to the 2015 Spectrum, the number of PWID
was estimated at 104,804. This estimate is based on an ex-
trapolation of data from the mapping that was conducted
as part of the 2011 IBBS. For the purpose of consistency
of methodology over time, the National AIDS Control
Programme is using the 2015 Spectrum PWID size esti-
mate to inform relevant national planning processes, such
as the development of Pakistan AIDS Strategy III and the
HIV Concept Note which was submitted to the Global
Fund in April 2015.
Status of the current harm reduction response
Policy, strategy and legal framework
In September 2007, the HIV & AIDS Prevention, and
Treatment Act, was finalised. The Act aims at “prevent-
ing the HIV from becoming established in the general
population, particularly in the most-at-risk and vulner-
able populations, and to provide for the care, treatment
and support of persons living with HIV and AIDS”.
The Government of Pakistan developed a National HIV
and AIDS Policy in 2007 [17] which remains in draft form.
The HIV and AIDS Policy notes that the focus of HIV
prevention efforts needs to be on “groups most affected
by HIV and AIDS: injecting drugs users and people who
engage in sexual behaviour that puts them at risk”. The
prevention strategies, envisaged in the Policy include
“needle and syringe outreach to injecting drug users
and referral to drug treatment services”. The National
HIV and AIDS Strategic Framework 2007–2012 aimed at
“translating the National Policy on HIV and AIDS by pro-
viding strategic guidance to the planning of programmes,
projects and interventions by various stakeholders” [18].
Following the 18th Amendment and the subsequent
devolution in 2011, the Ministry of National Health
Services, Regulation and Coordination was devolved to
the provinces. Since devolution, the Provincial AIDS
Control Programmes developed Provincial AIDS Con-
trol Strategies which are available in all four provinces.
One of the three outcome areas in each of these strat-
egies relates to reduction of HIV Prevalence among
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Key Affected Populations (including prisoners) main-
taining prevalence at below 0.1 % in the general
population.
The Ministry of Narcotics Control of the Government
of Pakistan has a Drug Control Master Plan (2010–2014)
and a National Anti Narcotics Policy (2010) updated in
August 2011. The objectives of the Drug Control Master
Plan and National Anti Narcotics Policy are threefold:
(i) supply reduction, (ii) demand reduction and (iii)
international cooperation. With regard to demand re-
duction, a key focus of the National Anti Narcotics Policy
is “enhancing demand prevention efforts focusing through
education and community mobilisation campaign and
projects”, including to “develop special training and treat-
ment programmes on drug abuse and drug related HIV/
AIDS prevention/rehabilitation” in jails. Furthermore, the
National Anti Narcotics Policy notes that an estimated
40 % of Pakistan’s prison population use drugs. In view of
the scale of drug use among prisoners, the Policy notes
that, in addition to drug demand reduction efforts, “drug
treatment and rehabilitation facilities will be extended to
key jails”.
Availability and programme coverage of recommended
HIV services among PWID
Under the leadership of the National AIDS Control
Programme (NACP), the Provincial AIDS Control Pro-
grammes (PACPs), in partnership with non-governmental
organisations, are implementing several of the nine rec-
ommended HIV prevention, treatment and care services
at community level [19], including needle and syringe
programme, HIV testing and counselling and referral to
antiretroviral treatment, care and support for those who
test HIV positive. The national HIV response is imple-
mented in close cooperation between the NACP, PACPs,
UN agencies, NGOs and CSOs with the support of donor
partners.
Needle and syringe programme (NSP) has been oper-
ational since 2003–2004 (NSF II) in Pakistan. The
programme is implemented by the Provincial AIDS
Control Programmes and Nai Zindagi, one of the two
principal recipients (PRs) of the Global Fund grant for
harm reduction from the round 9 as well as a range of
a sub-recipient NGO implementing partners. In Punjab
province, the Provincial AIDS Control Programme is
implementing NSP in 9 cities. With support from the
round 9 funding, Nai Zindagi is covering another 13
cities/districts in Punjab province, 10 cities/districts in
Sindh province and 2 cities in Balochistan province,
respectively. Data from a total of 28 sites supported by
the GFATM indicate that there were some 39,935 PWID,
or some 38 % of the estimated 104,804 PWID in the coun-
try, registered with harm reduction programmes supported
by the GFATM between 2012 and 2014 [20]. A total of
1484 spouses of PWID were also registered and receiving
services.
As per the programme monitoring data, the number of
needles and syringes per PWID per year has increased from
131 per PWID per year in 2011 to 470 per PWID per year
in 2014 [21]. Several factors, including drug use-related
arrests by police, continue to hamper expansion of the
needle and syringe programme. For example, in a survey of
HIV treatment access among 545 people who use drugs by
the Association of People Living with HIV/AIDS (APLHIV)
in 2013 and 2014, 48.3 % reported having been arrested or
detained for drug use [22].
Comparison of behavioural and HIV prevalence data
among PWID from the 2011 IBBS in cities that have harm
reduction interventions and in cities without intervention
found higher rates of use of sterile needles and syringes
(59 vs. 27 %), higher rates of condom use (24 vs. 11 %)
and higher levels of HIV knowledge in the intervention
cities [23]. However, HIV prevalence among PWID in
the intervention cities remained unchanged in the city
of Faisalabad (13 %), and prevalence was found to have
increased in Karachi (26–30 %) and Lahore (4–7 %)
[23]. Low level of programmatic coverage of harm
reduction services is considered among the main fac-
tors in fuelling the HIV epidemic among street-based
injectors.
People who inject drugs are disproportionally less likely
to receive treatment for their HIV infection compared with
people who do not inject drugs, as reported in a global
review of coverage of antiretroviral therapy (ART) among
PWID [24]. One of the underlying reasons for the low
uptake of and access to ART in this population is low
uptake of HIV testing among PWID which in Pakistan
remains very low compared with other countries in
Asia. The 2011 IBBS indicated that 9.1 % of PWID
had tested for HIV in the previous 12 months from
having been interviewed. Of the 11,038 registered
people living with HIV, 5019 (45.5 %) were receiving
antiretroviral treatment as of the end of December
2014. While the 2015 Spectrum estimates that 54,541
adults and 1835 children would be eligible for ART,
the ART coverage among adults in need of treatment
is 9.2 % and children in need of treatment is 5.6 %,
respectively.
In a survey of 545 people who use drugs by the Asso-
ciation of People Living with HIV (APLHIV), 298
(54.7 %) had tested for HIV while the number of study
respondents who reported being on ART was only 23
(4.2 %) despite a high overall prevalence of HIV in the
population of people who use drugs [22]. In the same
survey, 25.3 % (n = 138) reported having been denied
access to medical care “in the recent past” and 28.1 %
(n = 153) had been denied admission in hospital.
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Once on ART, adherence to HIV medicines among
PWID remains a challenge and is increasingly raising con-
cerns about possible resistance to antiretroviral (ARV)
drugs , including second line ARVs. It is well documented
that people who use drugs are especially vulnerable to
poor adherence to antiretroviral therapy [25] which is not
only a barrier to viral suppression in the HIV-positive in-
dividual but also negatively impacts on prevention of on-
ward transmission of HIV at population level [26].
Available data on adherence to ART among PWID in
Pakistan also indicates lower adherence to ART among
PWID compared to HIV patients who do not inject drugs.
A prospective study of 162 HIV-positive male patients, in-
cluding 81 PWID and 81 patients who did not inject drugs,
in an ART centre in a major public hospital in Islamabad
over a 5-year period found that 41 (50.6 %) of the PWID
were lost to follow-up compared with two (2.5 %) of the
non-injection drug users who were lost to follow-up at the
end of the study. Furthermore, the HIV treatment adher-
ence levels ranged from 90.1 % among patients who did
not inject drugs compared to 19.8 % among HIV patients
who injected drugs, respectively [27]. Another recent sur-
vey in Jinnah Hospital in Lahore found that, of the 869 pa-
tients who had ever been registered with the ART clinic,
273 (31.4 %) were PWID. Only 32.6 % of the HIV-positive
PWID had ever been put on HIV treatment compared with
54 % of the non-PWID. Over a 6-month follow-up period,
25 % of the PWID who were registered with the ART clinic
continued on treatment while the rest were lost to follow-
up [27].
A meta-analysis of 38 studies that assessed adherence
to ART among people who use drugs living with HIV
found higher adherence among patients who were receiving
opioid substitution therapy (OST) [28]. OST, a key compo-
nent of the comprehensive package of nine HIV services
recommended by WHO, UNODC and UNAIDS, is yet to
be introduced and scaled up in Pakistan. As of now,
Pakistan is the only country in Asia with large-scale use of
opioids that does not have a national OST programme.
Yet, leading HIV specialist physicians in the country
report that absence of OST, which would help to stabilise
HIV patients majority of whom are people who inject
drugs, is one of the main barriers to uptake of and ad-
herence to HIV treatment among HIV-positive PWID.
While OST was reflected and funding earmarked in the
round 9 of the GFATM proposal; it was not possible for
the principal recipients to implement the activity due
to the absence of an enabling policy environment for
the intervention.
A Technical Steering Committee (TSC) for opiate substi-
tution therapy (OST) was established by the Ministry of
National Health Services (M/o NHSR & C), Regulations
and Coordination in 2013. The Chairman of the TSC
was Secretary, M/o NHSR & C and Vice Chair was
Director General, M/o NHSR & C. The National AIDS
Control Programme was the designated Secretariat of
the TSC. Members of the TSC included representatives
of the Narcotics Control Division, Anti Narcotics Force,
Drug Regulatory Authority, Managers of the Provincial
AIDS Control Programmes, eminent psychiatrists, Nai
Zindagi, representative of the drug user community,
UNAIDS, UNODC and WHO.
Under the auspices of the OST TSC, the WHO-UNODC
Joint Programme on Drug Dependence Treatment and
Care supported a pilot study on the use of buprenorphine
for treatment of opioid-dependent people in 2013. The
pilot feasibility study was implemented by the Institute of
Psychiatry and the Narcotics Control Division in partner-
ship with the National HIV/AIDS Control Programme,
UNODC Country Office Pakistan, WHO and UNAIDS.
A total of 210 individuals enrolled in the pilot of whom
80 were availing of the OST programme as of Decem-
ber 2013. Analysis of the baseline and follow-up data
found a significant reduction in heroin use and inject-
ing among patients receiving treatment as well as sig-
nificant improvements in health and quality of life
among those on treatment. One of the major challenges
faced by the pilot project was unavailability of bupre-
norphine in the required strength as absorption of a
large number of crushed tables sublingually was a prac-
tical challenge for the patients. Despite the challenges,
73 % of the patients were retained in treatment at
12 months.
Despite ongoing advocacy on the importance of intro-
duction and expansion of OST for the purpose of reducing
demand for injecting of opiates, treatment of depend-
ence on opioids and for control of HIV and hepatitis C
transmission, pharmacologically assisted treatment of
dependence on opioids remains unavailable as of now.
Possible introduction of pharmacologically assisted
treatment will require approval of registration of
buprenorphine in the required dose of 2 and 8 mg sub-
lingual tablets by the Drug Regulatory Authority of
Pakistan (DRAP) which is currently under consider-
ation by the DRAP.
Following a mid-term review of the Provincial AIDS
Control Strategies, the National AIDS Control Programme
has finalised the Pakistan AIDS Strategy III (PAS III). The
PAS III recognises the important role of OST in HIV pre-
vention and treatment. As part of the PAS III, a separate
strategy for OST has been developed by the NACP, with
support from UNODC, UNAIDS and WHO. The OST
strategy, which has been reflected in the PAS III and the
HIV Concept Note for the Global Fund, proposes a phased
approach to introduction and expansion of OST consisting
of (i) phase 1—preparatory phase (2015 through to mid
2016), (ii) phase 2—implementation of OST service delivery
(mid 2016–December 2017) and (iii) phase 3—scale up and
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implementation of OST service delivery in an additional 13
cities (2018–2020).
Availability of HIV services in prisons
Access to HIV prevention, treatment and care services, rec-
ommended by UNODC, ILO, UNDP, WHO and UNAIDS
[29], is limited and mostly focused on general aware-
ness raising among prisoners and prison management
staff. A scan of service provision in prisons in 2014 by
UNODC found that ART was available on a limited
scale for prisoners in some prisons in two out of four
main provinces. For example, in Punjab province, 42
prisoners were receiving ART, and in Sindh province,
six prisoners were on ART as of April 2014. Condoms
were reportedly available in prisons in Sindh province
while needle and syringe programme remains unavail-
able in prisons. A series of capacity building training
workshops have been organised by UNODC during 2013
and 2014 with a total of 150 prison management staff,
including prison administration staff and psychologists
having been trained on prevention of drug use and HIV
prevention in prisons in the four main provinces. Following
organisation of a national coordination meeting on HIV
services in prisons in 2014, UNODC Pakistan Country
Office, in coordination with the NACP, will be supporting
organisation of provincial stakeholder consultations on
prisons and HIV, aimed at discussing and agreeing on
expansion of HIV services in prisons building on what is
already being implemented in prisons.
Conclusions
A key component of the comprehensive package of ser-
vices, opioid substitution therapy (OST), recommended by
WHO, UNODC and UNAIDS, is yet to be introduced and
scaled up in Pakistan. Given that an estimated 430,000
people inject drugs, mostly opiates, introduction and
expansion of OST that is accessible to large numbers
of people who have developed dependence on opioids
is critical. The absence of OST, which would help to
stabilise ART patients and promote adherence to ART
among patients majority of whom are PWID, is one of
the main barriers to treatment adherence.
Ensuring access to and adherence to ARVs among
people living with HIV, especially those who inject drugs,
has the potential to prevent much of the ongoing trans-
mission of HIV in Pakistan. Given low rates of HIV testing
and counselling overall, and among PWID in particular,
there is a need to explore new approaches that will attract
much larger numbers of PWID to test for HIV so that
those who test positive can benefit from treatment. Even-
tual introduction of OST will greatly improve adherence
to ART, leading to the suppression of viral load among
HIV-positive PWID and consequently averting new cases
of transmission of HIV from this population.
The voice of people who inject drugs is mostly silent in
national policy making, planning, implementation, moni-
toring and evaluation processes. With support from the
International Network of People who use Drugs (INPUD)
and Mainline, The Association of People Living with HIV/
AIDS (APLHIV) has in 2015 launched a Drug Users Net-
work (“DUNE”). The mission of DUNE is to mobilise
community leadership in order to influence laws, policies,
programmes and funds through meaningful involvement
of people who use drugs. It is anticipated that the forma-
tion of such a national network will enhance the represen-
tation and voice of people who use drugs in relevant fora.
The PAS III has prioritised prevention, treatment
and care services for key populations, including PWID
and prisoners. This approach remains the cornerstone
of Pakistan’s HIV response proposed for funding by
the Global Fund in addition to the financial resources
that are available through the provincial and national
“PC1s” (costed work plans). While the epidemic remains
concentrated among key populations and their networks,
there is no room for complacency given the large
population of PWID and continued high prevalence of
HIV among PWID in the country.
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